Review: Natalizumab in the treatment of multiple sclerosis

Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

(2009) Ray Gani et al.   PHARMACOECONOMICS

Allergic and Nonallergic Delayed Infusion Reactions During Natalizumab Therapy

(2008) Kerstin Hellwig et al.   ARCHIVES OF NEUROLOGY

Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab

(2008) Maria del Pilar Martin   ARCHIVES OF NEUROLOGY

Is natalizumab overshooting its rebound?

(2008) R. J. Fox et al.   NEUROLOGY

Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis

(2008) John T. Mullen et al.   NEW ENGLAND JOURNAL OF MEDICINE

More on Melanoma with Transdifferentiation

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Reply to “‘Thinking without thinking’ about natalizumab and PML”

(2007) Sidney Houff et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES